# Prostate Cancer Program

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2023 · $183,249

## Abstract

Prostate Cancer Program: Summary/Abstract
The overarching scientific goal of the HDFCCC Prostate Cancer (PR) Program is to use a team approach to
advance the understanding of tumor biology and drive translation into more effective and targeted treatment.
This is done through translational research spanning discovery bench science to clinical application and back.
The PR Program also seeks to specifically address the burden of prostate cancer and disparities in outcomes
among patients within the catchment area. The result will be a reduction the morbidity and mortality associated
with prostate cancer and its treatments by leveraging a deep understanding of the disease at the biologic,
clinical, and population levels. The PR Program approaches this mission with transdisciplinary research that is
richly collaborative and translational, organized around three specific aims: (1) to discover molecular features
and drivers of prostate cancer; (2) to develop and validate biomarkers and models to predict outcomes in men
with prostate cancer; and (3) to develop clinical interventions to improve outcomes for men with prostate
cancer.

## Key facts

- **NIH application ID:** 10712677
- **Project number:** 2P30CA082103-24
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** ERIC J SMALL
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $183,249
- **Award type:** 2
- **Project period:** 1999-08-05 → 2028-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10712677

## Citation

> US National Institutes of Health, RePORTER application 10712677, Prostate Cancer Program (2P30CA082103-24). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10712677. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*